<DOC>
	<DOC>NCT01192438</DOC>
	<brief_summary>The purpose of this study is to evaluate the safety of MRI-guided laser-induced thermal therapy of biopsy confirmed low-risk prostate cancer.</brief_summary>
	<brief_title>Laser Based Focal Ablation of Low Grade Prostate Cancer</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>Male, 45 years of age or older Diagnosis of prostate adenocarcinoma Clinical stage T1c or T2a Gleason score of 7 or less A minimum of 12 biopsy cores sampled during diagnostic biopsy Three or fewer biopsy cores with prostate cancer No single biopsy core with greater than 50% of tumor involvement A radiographically visible prostate lesion on MRI with concordance to biopsy sextant A documented Karnofsky performance status of at least 70 Estimated survival of 20 years or greater, as determined by treating physician Ability to give informed consent Previous surgery, radiation, or androgen deprivation therapy for prostate cancer Presence of any condition (e.g., metal implant, shrapnel) not compatible with MRI History of previous pelvic radiation Severe lower urinary tract symptoms as measured by an International Prostate Symptom Score (IPSS) of 20 or greater. (See Appendix A) History of other primary nonskin malignancy within previous three years</criteria>
	<gender>Male</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>prostate</keyword>
	<keyword>cancer</keyword>
	<keyword>ablation</keyword>
	<keyword>laser-induced</keyword>
	<keyword>focal therapy</keyword>
</DOC>